Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker BAX · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Nov 3, 2026 | PROPOFOL PROPOFOL | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA203421 ↗ |
| Oct 28, 2026 | IFOSFAMIDE, IFEX IFOSFAMIDE; MESNA | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA019763 ↗ |
| Oct 6, 2026 | SODIUM BICARBONATE SODIUM BICARBONATE | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Labeling | NDA218524 ↗ |
| Oct 2, 2026 | FOSAPREPITANT FOSAPREPITANT DIMEGLUMINE | BAX Baxter Hlthcare Corp | Generic (ANDA), supplement Labeling | ANDA211860 ↗ |
| Sep 24, 2026 | DAPZURA RT DAPTOMYCIN | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Labeling | NDA213645 ↗ |
| Sep 18, 2026 | ROCURONIUM BROMIDE ROCURONIUM BROMIDE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA219260 ↗ |
| Sep 11, 2026 | METOCLOPRAMIDE HYDROCHLORIDE METOCLOPRAMIDE HYDROCHLORIDE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA217072 ↗ |
| Aug 31, 2026 | CEFAZOLIN IN DEXTROSE CEFAZOLIN SODIUM | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Labeling | NDA207131 ↗ |
| Aug 31, 2026 | OXACILLIN OXACILLIN SODIUM | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA050640 ↗ |
| Aug 14, 2026 | SODIUM BICARBONATE SODIUM BICARBONATE | BAX Baxter Hlthcare Corp | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA218524 ↗ |
| Aug 7, 2026 | PerClot® Polysaccharide Hemostatic System Agent, absorbable hemostatic, non-collagen based | BAX Baxter Healthcare Corporation | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P210036 ↗ |
| Aug 7, 2026 | PerClot® Polysaccharide Hemostatic System Agent, absorbable hemostatic, non-collagen based | BAX Baxter Healthcare Corporation | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P210036 ↗ |
| Aug 6, 2026 | LEVETIRACETAM LEVETIRACETAM | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA208458 ↗ |
| Jul 28, 2026 | DIAZEPAM DIAZEPAM | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA219882 ↗ |
| Jul 8, 2026 | EPHEDRINE SULFATE EPHEDRINE SULFATE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA216740 ↗ |
| Jul 2, 2026 | LEVOCARNITINE LEVOCARNITINE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA217896 ↗ |
| Jun 25, 2026 | CEFEPIME CEFEPIME HYDROCHLORIDE | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA050817 ↗ |
| Jun 11, 2026 | DEXTROSE DEXTROSE | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA016694 ↗ |
| Jun 11, 2026 | DEXTROSE DEXTROSE | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA016673 ↗ |
| Jun 9, 2026 | VANCOMYCIN HYDROCHLORIDE VANCOMYCIN HYDROCHLORIDE | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA050671 ↗ |
| Jun 8, 2026 | PerClot® Polysaccharide Hemostatic System Agent, absorbable hemostatic, non-collagen based | BAX Baxter Healthcare Corporation | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P210036 ↗ |
| Apr 15, 2026 | DEXMEDETOMIDINE HYDROCHLORIDE DEXMEDETOMIDINE HYDROCHLORIDE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA208103 ↗ |
| Apr 3, 2026 | PHENYLEPHRINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA217032 ↗ |
| Mar 30, 2026 | EPINEPHRINE EPINEPHRINE | BAX Baxter Hlthcare Corp | New drug (NDA) New Combination and New Formulation or… | NDA220626 ↗ |
| Mar 10, 2026 | DOXORUBICIN HYDROCHLORIDE LIPOSOME, DOXIL DOXORUBICIN HYDROCHLORIDE | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Labeling | NDA050718 ↗ |
| Feb 26, 2026 | PHYTONADIONE PHYTONADIONE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA216852 ↗ |
| Feb 6, 2026 | NOREPINEPHRINE BITARTRATE NOREPINEPHRINE BITARTRATE | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Manufacturing (CMC) | NDA214313 ↗ |
| Jan 16, 2026 | WAVE Clinical Platform (2.0.000) | BAX Baxter Healthcare Corp/ Excel Medical | Device clearance (510(k)) Traditional | K250135 ↗ |
| Jan 8, 2026 | MAGNESIUM SULFATE MAGNESIUM SULFATE | BAX Baxter Hlthcare Corp | Generic (ANDA), supplement Manufacturing (CMC) | ANDA211966 ↗ |
| Dec 16, 2025 | Welch Allyn FlexiPort Blood Pressure Cuffs (FlexiPort Blood… | BAX Baxter Healthcare Corporation | Device clearance (510(k)) Traditional | K251745 ↗ |
| Nov 5, 2025 | POTASSIUM CHLORIDE IN LACTATED RINGERS AND DEXTROSE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLO… | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA019367 ↗ |
| Nov 5, 2025 | LACTATED RINGERS CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODI… | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA016682 ↗ |
| Nov 5, 2025 | LACTATED RINGERS AND DEXTROSE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLO… | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA016679 ↗ Letter or label ↗ |
| Oct 2, 2025 | SEVOFLURANE SEVOFLURANE | BAX Baxter Hlthcare | Generic (ANDA), supplement Labeling | ANDA075895 ↗ |
| Sep 23, 2025 | BREVIBLOC, ESMOLOL HYDROCHLORIDE ESMOLOL HYDROCHLORIDE | BAX Baxter Hlthcare | New drug (NDA), supplement Manufacturing (CMC) | NDA019386 ↗ |
| Sep 17, 2025 | KETAMINE HYDROCHLORIDE KETAMINE HYDROCHLORIDE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA219684 ↗ |
| Jul 29, 2025 | CEFEPIME CEFEPIME HYDROCHLORIDE | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA050817 ↗ |
| Jul 28, 2025 | SIGMA Spectrum Infusion Pump with Master Drug Library | BAX Baxter Healthcare Corporation | Device clearance (510(k)) Traditional | K251640 ↗ |
| Jul 28, 2025 | Spectrum IQ Infusion System with Dose IQ Safety Software (3… | BAX Baxter Healthcare Corporation | Device clearance (510(k)) Traditional | K251636 ↗ |
| Jul 24, 2025 | CLINOLIPID OLIVE OIL; SOYBEAN OIL | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Labeling | NDA204508 ↗ |
| Jul 17, 2025 | HYDRALAZINE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE | BAX Baxter Hlthcare Corp | Generic (ANDA) UNKNOWN | ANDA219797 ↗ |
| Jul 11, 2025 | CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE | BAX Baxter Hlthcare | Generic (ANDA), supplement Labeling | ANDA040745 ↗ |
| Jun 24, 2025 | METRONIDAZOLE METRONIDAZOLE | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA018657 ↗ |
| Jun 10, 2025 | TRANSDERM SCOP SCOPOLAMINE | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Manufacturing (CMC) | NDA017874 ↗ |
| May 29, 2025 | VANCOMYCIN HYDROCHLORIDE VANCOMYCIN HYDROCHLORIDE | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA050671 ↗ |
| Apr 30, 2025 | DAPZURA RT DAPTOMYCIN | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Labeling | NDA213645 ↗ Letter or label ↗ |
| Apr 25, 2025 | PerClot® Polysaccharide Hemostatic System Agent, absorbable hemostatic, non-collagen based | BAX Baxter Healthcare Corporation | Device approval (PMA), supplement Real-Time Process | P210036 ↗ |
| Apr 25, 2025 | TRANSDERM SCOP SCOPOLAMINE | BAX Baxter Hlthcare Corp | New drug (NDA), supplement Labeling | NDA017874 ↗ Letter or label ↗ |
| Mar 14, 2025 | METRONIDAZOLE METRONIDAZOLE | BAX Baxter Hlthcare | New drug (NDA), supplement Labeling | NDA018657 ↗ |
| Mar 14, 2025 | Solution Administration Sets | BAX Baxter Healthcare Corporation | Device clearance (510(k)) Traditional | K243529 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates